Assessment of male sexual function

Prostate Cancer and Prostatic Diseases

Volumn 4, Issue , 2001, Pages S7-S11

  Lukacs, B ^a  

^a HÔPITAL TENON   (France)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Questionnaires; Sexual dysfunction; Sexuality

Indexed keywords

EID: 1242310712     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500540     Document Type: Article

References (15)

1. Metz ME, Seifert MH. Men's expectations of physicians in sexual health concerns. J Sex Marital Ther 1990; 16: 79-88.
2. O'Leary MP et al. A brief male sexual function inventory for urology. Urology 1995; 46: 697-706.
3. Hansen BJ et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 1995; 76: 451-458.
4. Schou J, Holm NR, Meyhoff HH. Sexual function in patients with symptomatic benign prostatic hyperplasia. Scand J Urol Nephrol 1996; 30: 119-122.
5. Rosen RC et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-830.
6. Meuleman E et al. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int 2000; 87: 75-81.
7. Wagner G, Montorsi F, Auerbach S, Collins M. Sidenafil citrate (Viagra) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001; 56: 113-119.
8. Cappelleri JC et al. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999; 54: 346-351.
9. Cappelleri JC, Siegel RL, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile function and the erectile function domain of the International Index of Erectile Function. Urology 2000; 56: 477-481.
10. Rosen RC et al. International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-326.
11. Donovan JL et al. The ICS-'BPH' Study: the psychometric validity and reliability of the ICS-male questionnaire. Br J Urol 1996; 77 554-562.
12. Donovan JL et al. Using the ICSQoL to measure the impact of lower urinary tract symptoms on quality of life: evidence from the ICS-'BPH' Study. International Continence Society-Benign Prostatic Hyperplasia. Br J Urol 1997; 80: 712-721.
13. Lukacs B et al. Construction and validation of a BPH specific health related quality of life scale (with special attention to sexuality), for medical outcomes research studies. In: Cockett ATK et al (eds). Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia, Paris, 1993. Scientific Communication International Ltd: Jersey, Channel Islands. 1994, 139-143.
14. Lukacs B, Grange JC, Comet D, McCarthy C and the BPH Group in General Practice. Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice. Prostate Cancer PD 1998; 5: 276-283.
15. Lukacs B, Gomet D, Grange JC, Thibault P. Construction and validation of a short-term benign prostatic hyperplasia health-related quality of life questionnaire. Br J Urol 1997; 80 722-730.